Research Study: VESALIUS
Condition:
coronary heart disease
Study Sponsor: Amgen
Study Investigator: Thomas Knickelbine, MD
Study Contact: Ezi Ebere
Ezinwanyi.UbaniEbere@allina.com
612-863-4393
Every research study comes with its own unique risks and benefits; the study team will assess whether you’re an eligible candidate and ensure you’re provided with all the information you need to decide if participating is right for you.
About this Study:

This study will assess the effect of lowering low-density lipoprotein cholesterol (LDL-C) with evolocumab on major cardiovascular events in adults without a prior myocardial infarction (MI) or stroke who are at high risk of a cardiovascular event.
Eligibility Criteria:

  • Age: Adult subjects ≥ 50 (men) or ≥ 55 (women) to ˂ 80 years of age (either sex) and meeting lipid criteria
  • Low-density lipoprotein cholesterol (LDL-C) ≥ 90 mg/dL (≥ 2.3 mmol/L) or non‑high-density lipoprotein cholesterol (non-HDL) ≥ 120 mg/dL (≥ 3.1 mmol/L) at screening, or apolipoprotein B ≥ 80 mg/dL (≥ 1.56 µmol/L)
  • Evidence of at least one of the following at screening (without prior myocardial infarction or stroke):A. Significant coronary artery disease (CAD) B. Significant atherosclerotic cerebrovascular disease C. Significant peripheral arterial disease D. Diabetes mellitus
  • At least 1 high-risk feature

Interested in participating in this study?

Reach out to the study contact directly, or fill out this form and we will contact you and assess whether you are an eligible candidate!